EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

Evaluating Toxicity and Interaction Outcomes of Systemic Therapy and Stereotactic Ablative Radiation Therapy for Oligometastatic Disease: A Secondary Analysis of the Phase 2 SABR-5 Trial

Aiden Kooyman, Jee Suk Chang, Mitchell Liu, Will Jiang, Alanah Bergman, Devin Schellenberg, Benjamin Mou, Abraham Alexander, Hannah Carolan, Fred Hsu, Stacy Miller, Siavash Atrchian und 18 weitere

International Journal of Radiation Oncology*Biology*Physics · 2025

DOI: 10.1016/j.ijrobp.2025.03.079 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2025. Verfasst von Aiden Kooyman und 29 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. Hauptthemen laut MEDLINE: Radiosurgery, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Varian Medical Systems, AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Although stereotactic ablative radiation therapy (SABR) is known for low toxicity and safety, its combined use with specific systemic therapies requires further investigation. This study aims to evaluate the toxicity of SABR in combination with various systemic therapies. MATERIALS AND METHODS: A secondary analysis of the SABR-5 trial evaluated grade 2+ and 3+ toxicities post-SABR in patients who had received high-risk or non-high-risk systemic therapies before SABR at 4 predefined intervals: concurrent with SABR, 1 day to 1 week prior, 1 to 2 weeks prior, or 2 to 12 weeks prior. High-risk systemic therapy was a priori defined as drugs that may increase treatment toxicity when delivered in close proximity to SABR. This category encompasses cytotoxic chemotherapy, multitargeted tyrosine kinase inhibitors, CDK 4/6 inhibitors, EGFR inhibitors, anti-VEGF agents, and anti-CTLA-4 agents. RESULTS: Among 380 patients, grade 2+ toxicity rates were 17.3% (35/202) off systemic therapy, 19.2% (19/99) on non-high-risk therapy, and 42.9% (3/7) on high-risk therapy concurrent with SABR. Grade 3+ rates were 3.5% (7/202), 4.0% (4/99), and 28.6% (2/7), respectively. On multivariable analysis, concurrent use of high-risk systemic therapy was associated with a higher risk of grade 3+ toxic effects (OR, 14.88; P = .009). No significant risk was noted when high-risk drugs were used within 1 week, 2 weeks, or 2 to 12 weeks of SABR or with any non-high-risk drugs. Grade 2+ toxic effects associated with concurrent high-risk systemic therapy were primarily bone/pain related. Increased tumor diameter also elevated grade 2+ toxicity risk (per 1 cm increment; G2+ OR, 1.19; P < .001). CONCLUSION: Concurrent use of high-risk drugs has demonstrated a potential of increased SABR-related toxicity, warranting caution in their concurrent use with SABR. In contrast, combining non-high-risk drugs (eg, hormonal therapy) with SABR did not increase risk. Further research is essential to identify risks associated with this therapeutic combination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadiosurgeryAntineoplastic AgentsHumansMaleAgedFemaleMiddle AgedAged, 80 and overAdultCombined Modality TherapyTreatment OutcomeNeoplasm MetastasisProtein Kinase Inhibitors

Substanzen

Antineoplastic AgentsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
  • Department of Radiation Oncology, BC Cancer-Vancouver, University of British Columbia, Vancouver, British Columbia, Canada; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
  • Department of Radiation Oncology, BC Cancer-Vancouver, University of British Columbia, Vancouver, British Columbia, Canada.
  • Department of Radiation Oncology, BC Cancer-Surrey, University of British Columbia, Surrey, British Columbia, Canada.
  • Department of Radiation Oncology, BC Cancer-Kelowna, University of British Columbia, Kelowna, British Columbia, Canada.
  • Department of Radiation Oncology, BC Cancer-Victoria, University of British Columbia, Victoria, British Columbia, Canada.

Förderung

  • Varian Medical Systems
  • AstraZeneca

Zitieren

APA

Kooyman, A., Chang, J. S., Liu, M., Jiang, W., Bergman, A., Schellenberg, D., Mou, B., Alexander, A., Carolan, H., Hsu, F., Miller, S., Atrchian, S., Chan, E., Ho, C., Mohamed, I., Lin, A., Berrang, T., Bang, A., Chng, N., …, & Baker, S. (2025). Evaluating Toxicity and Interaction Outcomes of Systemic Therapy and Stereotactic Ablative Radiation Therapy for Oligometastatic Disease: A Secondary Analysis of the Phase 2 SABR-5 Trial. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2025.03.079

Vancouver

Kooyman A, Chang JS, Liu M, Jiang W, Bergman A, Schellenberg D, et al. Evaluating Toxicity and Interaction Outcomes of Systemic Therapy and Stereotactic Ablative Radiation Therapy for Oligometastatic Disease: A Secondary Analysis of the Phase 2 SABR-5 Trial. International Journal of Radiation Oncology*Biology*Physics. 2025. doi:10.1016/j.ijrobp.2025.03.079

BibTeX
@article{Kooyman2025,
  author = {Kooyman, Aiden and Chang, Jee Suk and Liu, Mitchell and Jiang, Will and Bergman, Alanah and Schellenberg, Devin and Mou, Benjamin and Alexander, Abraham and Carolan, Hannah and Hsu, Fred and Miller, Stacy and Atrchian, Siavash and Chan, Elisa and Ho, Clement and Mohamed, Islam and Lin, Angela and Berrang, Tanya and Bang, Andrew and Chng, Nick and Matthews, Quinn and Huang, Vicky and Mestrovic, Ante and Hyde, Derek and Lund, Chad and Pai, Howard and Valev, Boris and Lefresne, Shilo and Tyldesley, Scott and Olson, Robert and Baker, Sarah},
  title = {Evaluating Toxicity and Interaction Outcomes of Systemic Therapy and Stereotactic Ablative Radiation Therapy for Oligometastatic Disease: A Secondary Analysis of the Phase 2 SABR-5 Trial},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2025},
  doi = {10.1016/j.ijrobp.2025.03.079}
}
Kostenlos starten →